
For adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy. See full indication »
For adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy. See full indication »
Getting a lung cancer diagnosis and starting a new treatment can be overwhelming. You may have a lot of questions. Here are answers to some questions you may have about IMFINZI and lung cancer. Remember, your doctor is the best resource for answering specific questions about your treatment.
Click on the + to view answers to frequently asked questions.
ES-SCLC is an aggressive type of lung cancer that has spread to both lungs or to other parts of the body. It is the most common type of SCLC. Almost 70% of people with SCLC have the extensive stage form when they are diagnosed.
IMFINZI is an immunotherapy treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy.
Immunotherapy is a type of treatment that works with your immune system to find and attack cancer. IMFINZI may also attack healthy cells. Ask your doctor if an immunotherapy treatment is right for you.
Chemotherapy attacks all fast-growing cells, including cancer cells. Immunotherapy works with the immune system to find and attack cancer. IMFINZI and chemotherapy may also affect normal cells.
IMFINZI is an immunotherapy. It is a type of treatment that works with your immune system to find and attack cancer. IMFINZI may also affect healthy cells. IMFINZI and chemotherapy work together to treat extensive-stage small cell lung cancer (ES-SCLC).
IMFINZI and chemotherapy are combined to help fight ES-SCLC. Chemotherapy attacks fast-growing cells, so that immunotherapy can more readily attack the cancer. IMFINZI and chemotherapy may also affect normal cells.
IMFINZI is given as an intravenous (IV) infusion at your doctor’s office, the hospital, or infusion center. While your infusion times may vary, it usually takes about 60 minutes to get an IMFINZI infusion.
Treatment with IMFINZI is given in 2 phases:
Remember that every person is different. Talk to your doctor about how many treatments may be right for you.
While on IMFINZI, you may experience side effects. This is because IMFINZI can cause your immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.
IMFINZI may also cause serious side effects. They include:
The most common side effects of IMFINZI include when used with other anticancer medicines with SCLC include:
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of IMFINZI.
Please see Important Safety Information below and complete Prescribing Information.
There are a variety of helpful resources to provide you with treatment, access, and financial support.
See how IMFINZI + chemotherapy works to help fight ES-SCLC
Are you caring for someone with ES-SCLC?
IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.
IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called small cell lung cancer (SCLC). IMFINZI may be used with the chemotherapy medicines etoposide and carboplatin or cisplatin as your first treatment when your SCLC has spread within your lungs or to other parts of the body (extensive-stage small cell lung cancer, or ES-SCLC).
It is not known if IMFINZI is safe and effective in children.
Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with IMFINZI. Your healthcare provider will monitor you for these complications.
Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with IMFINZI. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with IMFINZI if you have severe side effects.
Before you receive IMFINZI, tell your healthcare provider about all of your medical conditions, including if you:
Females who are able to become pregnant
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects when used with other anticancer medicines with SCLC include nausea, hair loss, and feeling tired or weak.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called small cell lung cancer (SCLC). IMFINZI may be used with the chemotherapy medicines etoposide and carboplatin or cisplatin as your first treatment when your SCLC has spread within your lungs or to other parts of the body (extensive-stage small cell lung cancer, or ES-SCLC).
It is not known if IMFINZI is safe and effective in children.
Please click here for complete Prescribing Information, including Patient Information (Medication Guide).
IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.
IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called small cell lung cancer (SCLC). IMFINZI may be used with the chemotherapy medicines etoposide and carboplatin or cisplatin as your first treatment when your SCLC has spread within your lungs or to other parts of the body (extensive-stage small cell lung cancer, or ES-SCLC).
It is not known if IMFINZI is safe and effective in children.